Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
LIM and cysteine-rich domains protein 1 (LMCD1) is a multifunctional transcriptional cofactor belonging to the LIM-domain family of zinc finger proteins, featuring an N-terminal cysteine-rich domain and two C-terminal LIM domains[1][3]. LMCD1 acts primarily as a transcriptional corepressor and modulator, notably interacting with and repressing GATA6 and other GATA family transcription factors by inhibiting their DNA binding, thereby restricting tissue-specific gene activation in the heart and lungs[1][2][3]. LMCD1 regulates multiple biological processes including cardiac hypertrophy (through calcineurin/NFAT signaling), skeletal muscle growth, vascular smooth muscle proliferation, osteogenic differentiation (by stabilizing key osteogenic regulators such as RUNX2 and Smad1), as well as cancer cell migration and epithelial-to-mesenchymal transition[3][4]. Disease associations include a role in cardiomyopathy, vascular disorders, osteoporosis, and the progression of several cancers[1][3][4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on LIM and cysteine-rich domains protein 1 (LMCD1).